NasdaqGS:INSMBiotechs
Assessing Insmed (INSM) Valuation After Recent Share Price Weakness And Rare Disease Growth Hopes
Insmed (INSM) is back in focus after recent trading pulled the stock down about 21% over the past month and roughly 33% over the past 3 months, prompting fresh attention on its rare disease portfolio.
See our latest analysis for Insmed.
At a share price of US$106.24, Insmed has seen short term momentum fade, with the 30 day share price return down 21.4% and the year to date share price return down 40%, even though the 1 year total shareholder return is 57.3% and the 3 year total shareholder...